Cardiovascular risk factors: When should we treat?

Medical Journal of Australia

Volumn 178, Issue 3, 2003, Pages 101-102

  Tonkin, Andrew M ^a,b   Lim, Stephen S ^b   Schirmer, Henrik ^b  

^a NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGING; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; DRUG COST; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HUMAN; IMAGING SYSTEM; MEDICAL DECISION MAKING; MICROALBUMINURIA; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; VALIDATION PROCESS; AUSTRALIA; CORONARY ARTERY DISEASE; NOTE; PROGNOSIS; RISK FACTOR;

AUSTRALIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; HUMANS; PRACTICE GUIDELINES; PROGNOSIS; RISK FACTORS;

EID: 0038544095     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05092.x     Document Type: Editorial

References (15)

1. Law M, Wald NJ. Risk factor thresholds: Their existence under scrutiny. BMJ 2002; 324: 1570-1576.
2. Forge BH, Briganti EM. Lipid lowering and coronary heart disease risk: How appropriate are the national guidelines? Med J Aust 2001; 175: 471-475.
3. Australian Institute of Health and Welfare. National cardiovascular disease database online, 2001, Available at: http://www.aihw.gov.au/ (accessed Oct 2002).
4. Pharmaceutical Benefits Scheme expenditure report, April 2001 to March 2002 Available at: http://www.health.gov.au/pbs/stats.htm (accessed Oct 2002).
5. Lim S, Vos T, Peeters A, et al. Cost-effectiveness of prescribing statins according to Pharmaceutical Benefits Scheme criteria. Med J Aust 2001; 175: 459-464.
6. Simons LA, Simons J, Friedlander Y, et al. Risk functions for prediction of cardiovascular disease in the Australian elderly: The Dubbo study. Med J Aust 2002; 178: 113-116.
7. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham study. Am J Cardiol 1976; 38: 46-51.
8. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
9. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
10. New Zealand Guideline Group risk calculator. Available at: http://www.nzgg.org.nz/library/gl_complete/bloodpressure/index.cfm#contents (accessed Nov 2002).
11. Lipid Management Guidelines - 2001. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Med J Aust (Suppl 5 November). Available at: http://www.heartfoundation.com.au/prof/docs/lipid_guide_200 1.pdf (accessed Dec 2002).
12. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
13. Knuiman MW, Vu HT. Prediction of coronary heart disease mortality in Busselton, Western Australia: An evaluation of the Framingham, National Health Epidemiologic Follow-up Study, and WHO ERICA risk scores. J Epidemiol Community Health 1997; 51: 515-519.
14. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores. Results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
15. Bonneux L. Cholesterol-lowering therapy for smokers and non-smokers: A life-table analysis. Lancet 2000; 356: 2004-2006.